Accelerated atherogenesis and neointima formation in heparin cofactor II-deficient mice

Blood

Volumn 110, Issue 13, 2007, Pages 4261-4267

  Vicente, Cristina P ^a   He, Li ^b   Tollefsen, Douglas M ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; DERMATAN SULFATE; HEPARIN COFACTOR II; HIRUDIN; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; THROMBOGENESIS; ANIMAL; ATHEROSCLEROSIS; CAROTID ARTERY THROMBOSIS; GENETICS; INTIMA; METABOLISM; MOUSE MUTANT; PATHOLOGY; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; CAROTID ARTERY THROMBOSIS; CAROTID ARTERY, COMMON; DERMATAN SULFATE; HEPARIN COFACTOR II; MICE; MICE, MUTANT STRAINS; THROMBIN; TUNICA INTIMA;

EID: 39649087632     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-086611     Document Type: Article

References (35)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Tracy RP. Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest. 2003;124:49S-57S.
3. Coughlin SR. Protease-activated receptors in the cardiovascular system. Cold Spring Harb Symp Quant Biol. 2002;67:197-208.
4. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
5. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226-1232.
6. Stoop AA, Lupu F, Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol. 2000;20:1143-1149.
7. Aihara K, Azuma H, Takamori N, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation. 2004;109:2761-2765.
8. Schillinger M, Exner M, Sabeti S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb Haemost. 2004;92:1108-1113.
9. Takamori N, Azuma H, Kato M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation. 2004;109:481-486.
10. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258:6713-6716.
11. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourao PA. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta. 2005;1740:45-53.
12. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
13. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000;106:873-878.
14. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. 1998;102:1481-1488.
15. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 1997;90:944-951.
16. Vicente CP, He L, Pavao MS, Tollefsen DM. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood. 2004;104:3965-3970.
17. Semenkovich CF, Coleman T, Daugherty A. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J Lipid Res. 1998;39:1141-1151.
18. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998;273:30427-30434.
19. Leidenfrost JE, Khan MF, Boc KP, et al. A model of primary atherosclerosis and post-angioplasty restenosis in mice. Am J Pathol. 2003;163:773-778.
20. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res. 1976;8:859-867.
21. Tordjman K, Bernal-Mizrachi C, Zemany L, et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 2001;107:1025-1034.
22. Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone. Methods Enzymol. 1981;80(pt C):826-842.
23. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001;103:3044-3046.
24. Cooper ST, Neese LL, DiCuccio MN, Liles DK, Hoffman M, Church FC. Vascular localization of the heparin-binding serpins antithrombin, heparin cofactor II, and protein C inhibitor. Clin Appl Thrombosis/Hemostasis. 1996;2:185-191.
25. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem. 1987;262:169-175.
26. Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem. 2000;275:18085-18092.
27. Giri TK, Ahn CW, Wu KK, Tollefsen DM. Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2005;25:2689-2690.
28. Sie P, Dupouy D, Pichon J, Boneu B. Turnover study of heparin cofactor II in healthy man. Thromb Haemost. 1985;54:635-638.
29. Hatton MW, Hoogendoorn H, Southward SM, Ross B, Blajchman MA. Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. Am J Physiol. 1997;272:E824-E831.
30. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19:3014-3024.
31. Andrade-Gordon P, Derian CK, Maryanoff BE, et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther. 2001;298:34-42.
32. Chen X, Ren S, Ma MG, et al. Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. Atherosclerosis. 2003;169:31-40.
33. Buchanan MR, Brister SJ. Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulphate. Thromb Res. 1998;91:157-167.
34. Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem. 2001;276:20959-20965.
35. Aihara K, Azuma H, Akaike M, et al. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest. 2007;117:1514-1526.